Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapy

Annals of Oncology

Volumn 26, Issue 2, 2015, Pages 307-313

  Montagna, Emilia ^a   Bagnardi, V ^a,b   Viale, G ^a,c   Rotmensz, N ^a   Sporchia, A ^a   Cancello, G ^a   Balduzzi, A ^a   Galimberti, V ^a   Veronesi, P ^a   Luini, A ^a   Mastropasqua, M G ^a   Casadio, C ^a   Sangalli, C ^a   Goldhirsch, A ^a   Colleoni, M ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Breast cancer; Chemotherapy; HER2; Hormonal receptors; Neoadjuvant therapy; Surgery

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; ITALY; MAJOR CLINICAL STUDY; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR BIOPSY; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; BIOSYNTHESIS; BREAST NEOPLASMS; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; NEOADJUVANT THERAPY; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM, RESIDUAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84925343249     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu528     Document Type: Article

References (25)

1. Fisher B, Bryant J, Wolmark N et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-2685.
2. Guarneri V, Broglio K, Kau SW et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006; 24: 1037-1044.
3. Hennessy BT, Hortobagy GN, Rouzier RN et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 2005; 23: 9304-9311.
4. Kuerer HM, Newman LA, Smith TM et al. Clinical course of breast cancer patients with complete pathologic primary tumour and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460-469.
5. Colleoni M, Viale G, Zahrieh D et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 2004; 10: 6622-6628.
6. Lower EE, Glass E, Blau R et al. HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 2009; 113: 301-306.
7. Montagna E, Bagnardi V, Rotmensz N et al. Breast cancer subtypes and outcome after local and regional relapse. Ann Oncol 2012; 23(2): 324-331.
8. Chen S, Chen CM, Yu KD et al. Prognostic value of a positive-to-negative change in hormone receptor status after NCT in patients with hormone receptorpositive breast cancer. Ann Surg Oncol 2012; 19: 3002-3011.
9. Mittendorf EA, Wu Y, Scaltriti M et al. Loss of HER2 amplification following Trastuzumab based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 2009; 15(23): 7381-7388.
10. Jones RL, Salter J, A'Hern R et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2009; 116(1): 53-68.
11. Tanei T, Shimomura A, Shimazu K et al. Prognostic significance of Ki67 index after neoadjuvant chemotherapy in breast cancer. Eur J Surg Oncol 2011; 37(2): 155-161.
12. Miglietta L, Morabito F, Provinciali N et al. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients. Eur J Surg Oncol 2013; 39(10): 1046-1052.
13. von Minckwiz G, Schmitt WD, Loibl S et al. Ki67 measured after neoadjuvant chemotherapy for primary breast cancer. Clin Cancer Res 2013; 19(16): 4521-4531.
14. Dowsett M, Smith IE, Ebbs SR et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007; 99(2): 167-170.
15. Ellis MJ, Tao Y, Luo J et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 2008; 100(19): 1380-1388.
16. Colleoni M, Orvieto E, Nole` F et al. Prediction of response to primary chemotherapy for operable breast cancer. Eur J Cancer 1999; 35: 574-579.
17. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst 1998; 90: 1601-1608.
18. Prat A, Cheang MC, Marti´n M et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol 2013; 31(2): 203-209.
19. Cortazar P, Zhang L, Untch M et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; 384 (9938): 164-172.
20. Creighton CJ, Kent Osborne C, van de Vijver MJ et al. Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat 2009; 114: 287-299.
21. Osborne CK, Shou J, Massarweh S et al. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005; 11: 865s-870s.
22. Cancello G, Maisonneuve P, Rotmensz N et al. Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. Ann Oncol 2013; 24: 661-668.
23. International Breast Cancer Study Group Colleoni M, Gelber S et al. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol 2006; 24(9): 1332-1341.
24. Zhao J, Liu J, Chen K et al. What lies behind chemotherapy-induced amenorrhea for breast cancer patients: a meta-analysis. Breast Cancer Res Treat 2014; 145 (1): 113-128.
25. Rose DP, Davis TE. Effects of adjuvant chemo hormonal therapy on the ovarian and adrenal function of breast cancer patients. Cancer Res 1980; 40(11): 4043-4047.